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Aims Dyspnoea and pulmonary and/or peripheral congestion are the most frequent manifestations of acute heart failure
(AHF) and are important targets for therapy. We have assessed changes in dyspnoea, their relationship with mor-
tality, and the effects of the adenosine A1 receptor antagonist rolofylline on these endpoints in patients enrolled
in the PROTECT trial.
Methods
and results
PROTECT was a prospective, double-blind, placebo-controlled study assessing the effect of rolofylline in patients
hospitalized for AHF with dyspnoea, fluid overload, increased plasma natriuretic peptides, and mild-to-moderate
renal dysfunction. Early dyspnoea relief, prospectively defined as moderately or markedly better dyspnoea at both
24 and 48 h after the start of study drug administration, occurred in 49.8% of the patients. Early dyspnoea relief
was associated with greater weight loss and with reduced mortality at Days 14 and 30 [hazard ratio (HR) 0.28,
95% confidence interval (CI): 0.15, 0.50; and 0.35, 95% CI: 0.22, 0.55, respectively]. Rolofylline administration was
associated with an increase in the proportion of patients showing early dyspnoea relief (HR 1.30; 95% CI: 1.08,
1.57) and with a numerically lower mortality at 14 and 30 days, largely driven by the mortality due to HF [at 30
days, HR (95% CI, P-value): 0.65 (0.38–1.10, P ¼ 0.107)]. Rolofylline did not reduce episodes of in-hospital worsening
HF or post-discharge re-admissions, nor did it improve survival at 60 or 180 days.
Conclusion The present analysis from PROTECT demonstrated that more weight loss was associated with early dyspnoea relief
and reduced short-term mortality.
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Introduction
Dyspnoea and pulmonary and/or peripheral congestion are the
main clinical manifestations of acute heart failure (AHF) and are
important targets for therapy. Acute heart failure is associated
with a poor prognosis with deaths or rehospitalizations occurring
in 50% of the patients in the 3–6 months after discharge.1– 3 An
improvement in dyspnoea did not predict a reduction in deaths and
rehospitalizations in most previous drug intervention trials,4 –10
leading to concerns about the validity of dyspnoea as an endpoint,
especially when considered alone.11 This lack of association
between the effects of treatment on dyspnoea and on outcomes,
observed in previous studies, may have multiple causes. First, the
severity of dyspnoea as a symptom leading to hospitalization may
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vary and patients with milder symptoms and, thus, little room for
improvement may have been included in previous trials. Secondly,
drugs tested in recent AHF trials, such as nesiritide and levosimen-
dan,6,7 although providing some symptomatic relief, may have con-
comitant untoward effects (worsening renal function, hypotension,
and arrhythmias), which can modify outcomes independently from
their actions on dyspnoea.2,5,12 Thus, treatment may reduce symp-
toms but not the factors determining prognosis.
Many patients admitted with AHF have renal dysfunction, and
renal function worsens in 20–40% during hospitalization.13 –15
Since kidney dysfunction has been shown in epidemiological and ret-
rospective analyses of clinical trials to be associated with poorer
prognosis, it has been considered a potential cause of the poor
outcome of the patients with AHF.15–19 Adenosine A1 receptor
antagonists have been studied in patients with AHF because of
their diuretic effects with concomitant renal protection through glo-
merular afferent arteriole dilatation.20 Despite the pathophysiologi-
cal basis and the favourable results of initial studies with these
agents,21– 25 a large randomized, placebo-controlled trial, the
Placebo-controlled Randomized Study of the Selective A1 Adeno-
sine Receptor Antagonist Rolofylline for Patients Hospitalized with
Acute Decompensated Heart Failure and Volume Overload to
Assess Treatment Effect on Congestion and Renal FuncTion
(PROTECT), failed to show any effect of the adenosine A1 receptor
antagonist rolofylline on the primary and secondary endpoints.
However, there were suggestions that although rolofylline adminis-
tration had no beneficial effect on renal function, it might have
favourable effects on dyspnoea relief.26
The aim of this study is to analyse the clinical and prognostic
significance of changes in symptoms, namely dyspnoea, in the
patients enrolled in the PROTECT trial. With this purpose, we
performed a post hoc analysis of two of the three components
of the primary endpoint of the study, namely dyspnoea relief
and worsening heart failure (WHF) at Day 7, as well as additional
analyses of the effects of rolofylline on changes in dyspnoea up to
Day 7 and on short-term (in-hospital, 14, and 30 days) outcomes.
Methods
Inclusion criteria and study design
PROTECT was a multicentre, randomized, double-blind, placebo-
controlled trial in patients hospitalized for AHF conducted in North
America, Europe, Israel, and Argentina. A detailed description of the
study design has been published previously.26,27 For entry, patients
were required to have dyspnoea at rest or with minimal activity,
signs, and symptoms of volume overload requiring intravenous (i.v.)
loop diuretic therapy, impaired renal function (estimated creatinine
clearance of 20–80 mL/min by the Cockcroft–Gault equation cor-
rected for weight in oedematous or obese subjects ≥100 kg), and
elevated natriuretic peptide levels [brain natriuretic peptide (BNP)
≥500 pg/mL or N-terminal-pro-BNP (NT-proBNP) ≥2000 pg/mL].
Exclusion criteria are outlined in the design paper.27 Our study fulfilled
the requirements stated in the Declaration of Helsinki and it was
approved by the Ethics Committees at each participating centre.
Patients provided written informed consent.
Patients were randomized to receive rolofylline 30 mg administered
as a daily 4 h infusion for 3 days or placebo in a double-blind manner
according to a computer-generated randomization scheme; with a 2:1
rolofylline to placebo allocation. Heart failure signs ( jugular venous
pressure, rales, and oedema) and symptoms (dyspnoea and orthop-
noea) were evaluated by a physician just prior to the initial study
drug administration, daily through discharge on Day 6, and on Days
7 and 14. Patients’ self-reported symptoms (dyspnoea and general
well-being, each assessed utilizing a seven-point Likert scale of
change compared with baseline) were recorded daily from Days 2
to 6 or to discharge, if earlier, and at Days 7 and 14. Assessments at
Days 2 and 3 corresponded to measurements taken at 24 and 48 h
from study drug initiation. Blood samples for measurements of
serum creatinine, blood urea nitrogen, and uric acid were obtained
daily. Electrolytes, glucose, and complete blood count were measured
at baseline and Days 2, 7, and 14.
Follow-up evaluations at Days 7 and 14 included a physician assess-
ment, interim history, laboratory tests as noted above, and adverse
event evaluation. Adverse events were captured through Day 7;
serious adverse events were recorded through Day 14. Patients
were contacted by telephone to identify deaths and re-admissions
up to Day 60 and to assess vital status at Day 180.
Endpoints in PROTECT
The primary and secondary endpoints of the PROTECT study are
described in the design paper and have been recently reported.26,27
Briefly, the primary endpoint was an ordered composite endpoint
according to which patients were classified as success, unchanged, or
failure. Success was defined as patient-reported moderately or mark-
edly better dyspnoea using a seven-point Likert scale at both 24 and
48 h after the initiation of study drug administration in the absence
of any criterion for treatment failure. Failure included any of the fol-
lowing: death through Day 7, WHF or rehospitalization for HF
through Day 7, or persistent renal impairment. Worsening heart
failure was reported based on worsening signs and symptoms of HF
with resulting intensification of i.v. therapy for HF or mechanical circu-
latory or ventilator support. Persistent renal impairment was defined
as a serum creatinine increase of ≥0.3 mg/dL (26.5 mmol/L) from ran-
domization to Day 7, confirmed at Day 14, or the initiation of haemo-
filtration or dialysis through Day 7.
Endpoints of the present analysis
The endpoints of the present analysis were changes in symptoms
(i.e. dyspnoea relief and occurrence of WHF rate through Day 7
from randomization) and short-term (through Days 14 and 30) mor-
tality rates.
Dyspnoea relief was defined according to the definition used for the
primary endpoint of PROTECT, i.e. moderately or markedly better
dyspnoea at both 24 and 48 h randomization. The criteria for WHF
to Day 7 are defined above (see components of the primary endpoint).
Cause-specific mortality was analysed according to the adjudications of
the blinded Clinical Events Committee.
Statistical methods
Continuous variables are summarized as mean+ standard deviation
(SD), or as median and inter-quartile range (IQR). Statistical analyses
were performed using SAS version 9.2. All analyses were performed
by the intention-to-treat method. We used two-sided t-tests for stat-
istical comparisons. A P-value of ,0.05 was considered as threshold
for statistical significance. The Kaplan–Meier estimates of mortality
rates are given. In-hospital mortality for patients who were still hos-
pitalized at Day 30 was censored at 30 days. Hazard ratios (HRs)
were estimated from the Cox regression models, odds ratios (OR)
were estimated from logistic regression models, and mean differences
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Table 1 Baseline characteristics of the patients subdivided on the basis of relief of dyspnoea
Variable Dyspnoea relief
No (n5 1003) Yes (n 5 995) Difference (95% CI)a P-value
Age (years) 70+ 11 70+ 12 20.2 (21.2, 0.8) 0.710
Gender, males (%) 69 66 22.6 (26.8, 1.5) 0.204
Race, white/Caucasian (%) 95 96 0.6 (21.3, 2.4) 0.559
Weight (kg)
n 1002 995 20.4 (22.2, 1.3) 0.600
Mean+ SD 82.3+ 19.4 81.9+ 19.8
Baseline creatinine clearance (mL/min)
n 966 959 3.3 (1.5, 5.1) ,0.001
Mean+ SD 49.0+ 19.7 52.3+ 20.5
Baseline BNP (pg/mL)
n 258 272 214 (2231, 203) 0.901
Median (IQR) 1270.0 (818.0, 2235.0) 1229.0 (819.0, 2161.5)
Baseline NT-proBNP (pg/mL)b
n 749 742 2276 (21446, 894) 0.642
Median (IQR) 3000.0 (3000.0, 3732.0) 3000.0 (3000.0, 3879.0)
Systolic blood pressure (mmHg)
n 1003 994 1.8 (0.2, 3.3) 0.024
Mean+ SD 123.5+ 17.6 125.3+ 17.6
Diastolic blood pressure (mmHg)
n 1003 994 1.2 (0.3, 1.8) 0.137
Mean+ SD 73.0+ 11.8 74.2+ 11.9
Heart rate (b.p.m.)
n 1003 993 1.4 (0.5, 2.2) 0.222
Mean+ SD 79.0+ 15.3 80.5+ 15.5
Respiratory rate (b.p.m.)
n 945 963 0.1 (2.7, 1.0) 0.094
Mean+ SD 21.0+ 4.7 21.1+ 4.2
NYHA class prior to hospitalization
n 942 952 24.0 (27.5, 20.6) in %
NYHA class ¼ III or IV
0.012
Class I 0.9 1.1
Class II 15 19
Class III 50 52
Class IV 34 28
History of hypertension (%) 78 81 3.1 (20.6, 6.5) 0.104
History of atrial fibrillation/flutter (%) 55 54 21.4 (25.7, 3.0) 0.550
History of automatic internal cardiac defibrillators (%) 18 14 23.7 (26.9, 20.5) 0.025
History of congestive heart failure (%) 94 96 1.6 (20.4, 3.5) 0.113
History of diabetes mellitus (%) 48 43 24.8 (29.2, 20.4) 0.032
History of asthma, bronchitis, or chronic obstructive
pulmonary disease (%)
21 18 23.5 (26.9, 0.0) 0.053
History of ischemic heart disease (%) 72 68 24.4 (28.5, 20.4) 0.032
History of myocardial infarction (%) 50 49 20.1 (24.4, 4.3) 0.981
History of biventricular pacing (%) 12 8.7 22.8 (25.5, 20.2) 0.036
Left ventricular ejection fraction (% units)
n 488 470 21.1 (22.7, 0.5) 0.190
Mean+ SD 32.7+ 13.7 31.6+ 12.3
Continued
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were from linear regression models, adjusted for study (PROTECT-1
vs. -2) and region (USA, Canada, Western Europe, and Israel vs.
Central Europe and Argentina). Multivariable Cox regression analysis
was used to assess whether the relation between dyspnoea relief and
14 and 30 days mortality was independent from other variables
known to affect outcomes in AHF [namely age, New York Heart
Association (NYHA) class, serum creatinine, serum sodium, BNP
levels, and blood pressure]. P-values were calculated by the Wald
x2 analysis. No adjustment was made to this analysis for its post
hoc nature, and all P-values and confidence intervals (CIs) were
reported at their nominal levels. All analyses were stratified by
region and study.
Results
Patient characteristics and short-term
follow-up
Complete evaluations of early dyspnoea changes were obtained
in 1998 of 2033 patients enrolled in PROTECT. Thirty-five
patients were excluded since they did not have full data on dys-
pnoea relief. Early dyspnoea relief, using the rigorous definition
described above, occurred in only 49.8% of the patients.
Worsening heart failure through Day 7 occurred in 10.7% of
the patients; 3.6 and 4.8% of the patients died by Days 14 and
30, respectively.
Baseline characteristics of patients with and without dyspnoea
relief are presented in Table 1. Patients with dyspnoea relief had
lower NYHA class prior to admission, lower creatinine, and slightly
higher blood pressure. They were treated with less i.v. furosemide,
inotropes, or vasodilators and were more likely to receive
angiotensin-converting enzyme (ACE)-inhibitors or angiotensin
receptor blockers (ARBs) and b-blockers at discharge or up to
Day 7.
Patients who experienced dyspnoea relief had a greater average
decline in body weight over Days 2–4 after enrolment [mean
difference (95% CI), 20.48 (20.27, 20.70) kg], and this difference
was evident across all subgroups tested (Table 2). Baseline charac-
teristics of patients who survived to Days 14 and 30 are depicted in
Table 3.
Prognostic significance of early changes
in symptoms
Patients with early dyspnoea relief had numerically lower mortality
at both 14 and 30 days and the estimated magnitude of the
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Table 1 Continued
Variable Dyspnoea relief
No (n 5 1003) Yes (n 5 995) Difference (95% CI)a P-value
Prior ACE-inhibitors or ARB (%) 74 77 2.9 (20.9, 6.7) 0.130
Prior b-blockers (%) 77 76 20.2 (23.9, 3.5) 0.921
Prior aldosterone antagonists (%) 46 42 23.6 (27.8, 0.9) 0.120
Prior digoxin (%) 29 28 20.8 (24.7, 3.2) 0.701
Prior nitrates (%) 27 25 22.0 (25.8, 1.9) 0.314
ACE-inhibitors or ARB at discharge (%) 79 85 6.3 (2.9, 9.6) ,0.001
b-Blockers at discharge (%) 83 87 4.3 (1.2, 7.5) 0.007
Aldosterone antagonists at discharge (%) 59 61 1.4 (23.0, 5.7) 0.550
Digoxin at discharge (%) 35 31 24.4 (28.6, 20.3) 0.036
Nitrates at discharge (%) 23 17 26.0 (29.6, 22.5) 0.001
Days treated with study drug (%)
n 1003 995 2.2 (20.1, 4.4)






Total dose of i.v. loop diuretics from Days 1 to 7 (mg)
n 1003 995 2261 (2335, 2186) ,0.001
Median (IQR) 350.0 (160.0, 780.0) 227 (120.0, 420)
Treated with i.v. inotropes/vasopressors prior
to Day 7 (%)
11.4 3.2 28.2 (210.4, 25.9) ,0.001
Treated with vasodilators prior to Day 7 (%) 12.6 10.3 22.2 (25.0, 0.6) 0.121
n indicates number of patients.
aDifferences (95% CIs) are for patients with dyspnoea relief vs. those with no dyspnoea relief.
bMost of the equipments did not give values when NT-proBNP values were .3000 pg/mL.
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association was similar within subgroups defined by baseline vari-
ables, including variables related with the severity of HF before
hospitalization (NYHA class, serum creatinine or creatinine clear-
ance, systolic blood pressure, blood levels of natriuretic peptides;
Table 4). Of note, patients with dyspnoea relief had lower
NYHA class prior to admission, lower creatinine, and slightly
higher blood pressure. In addition, they were more likely to
receive ACE-inhibitors or ARBs and b-blockers at discharge or
up to Day 7. These suggest that patients with dyspnoea relief
had lower severity of HF. However, the association between dys-
pnoea relief and better survival, irrespective of the study group,
remained significant also after adjustment for age, NYHA class,
baseline BNP level, serum creatinine, serum sodium, and blood
pressure at multivariable analysis (Table 5).
In-hospital WHF was associated with a marked increase in the
risk of subsequent death at 14 days [HR (95% CI): 6.84 (4.12,
11.35)] and 30 days [HR (95% CI): 4.78 (3.10, 7.37)], compared
with the absence of this event, and this association was also con-
sistent across all subgroups examined (Table 6).
Effects of rolofylline administration
Compared with placebo, rolofylline administration was associated
with greater weight loss. At 72 h, the mean (95% CI) body weight
decrease in patients assigned to placebo was 22.55 (22.79,
22.3) kg compared with 22.98 (23.15, 22.81) kg with rolofyl-
line [mean (95% CI) treatment difference: 20.43 (20.73,
20.13) kg]. This occurred despite the initial administration of
similar doses of loop diuretics to the patients receiving rolofylline
and placebo and a numerically lower dose administered post-
randomization in rolofylline-treated patients (the mean+ SD
dose of furosemide was of 526+869 mg in the rolofylline
group vs. 553+850 mg in the placebo group; P ¼ NS).
Rolofylline administration was associated with higher proportion
of patients showing moderately to markedly better dyspnoea than
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Table 2 Average change in body weight (kg) on Days 2, 3, and 4 by dyspnoea relief
Variable Dyspnoea relief Group difference (95% CIs)
No Yes
All patients
n 978 989 20.5 (20.3, 20.7)
Mean+ SD 21.9+2.5 22.4+2.4
Median (IQR) 21.7 (20.7, 22.8) 22.0 (21.0, 23.7)
NYHA class I– III
n 600 681 20.3 (20.6, – 0.1)
Mean+ SD 21.9+2.6 22.2+2.3
Median (IQR) 21.7 (22.8, 20.7) 21.9 (23.3, 21.0)
NYHA class IV
n 321 266 20.8 (21.2, –0.4)
Mean+ SD 22.0+2.3 22.8+2.2
Median (IQR) 21.7 (22.9, 20.7) 22.3 (24.2, 21.2)
Baseline serum creatinine ,1.5 mg/dL (median)
n 423 495 20.5 (20.9, 20.2)
Mean+ SD 21.9+2.5 22.4+2.4
Median (IQR) 21.7 (22.8, 20.7) 22.0 (23.5, 21.0)
Baseline serum creatinine ≥1.5 mg/dL (median)
n 528 463 20.5 (20.8, 20.2)
Mean+ SD 22.0+2.5 22.4+2.5
Median (IQR) 21.7 (23.0, –0.7) 22.0, (23.7, 21.0)
Baseline creatinine clearance ,48 mL/min (median)
n 496 446 20.4 (20.7, 20.1)
Mean+ SD 21.9+2.6 22.3+2.3
Median (IQR) 21.6 (22.8, 20.6) 21.9 (23.4, 21.0)
Baseline creatinine clearance ≥48 mL/min (median)
n 453 511 20.6 (20.9, 20.2)
Mean+ SD 22.0+2.4 22.5+2.5
Median (IQR) 21.8 (22.9, –0.7) 22.2 (23.7, 21.0)
Early dyspnoea relief in acute heart failure 1523
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Table 3 Baseline characteristics of the patients subdivided on the basis of mortality at Days 14 and 30
Variable All-cause deaths at Day 14 P-value All-cause deaths at Day 30 P-value
No (n 5 1960) Yes (n5 73) Difference (95% CI)a No (n5 1927) Yes (n 5 106) Difference (95% CI)a
Age (years)
n 1960 73 4.5 (2.3, 6.6) 0.001 1927 106 3.5 (1.4, 5.6) 0.002
Mean+ SD 70.0+11.7 74.5+8.9 70.0+11.6 73.5+10.4
Gender, males (%) 67.2 64.4 22.8 (214.0, 8.4) 0.616 67 68 0.8 (28.3, 10.0) 0.852
Race, white/Caucasian (%) 95.2 98.6 3.4 (0.6, 6.3) 0.255 95 98 2.9 (0.1, 5.7) 0.233
Weight (kg)
n 1959 73 21.3 (25.6, 3.1) 0.589 1926 106 21.2 (25.0, 2.6) 0.548
Mean+ SD 82.1+19.6 80.8+18.2 82.1+19.6 80.9+19.1
Baseline creatinine clearance (mL/min)
n 1873 70 26.6 (210.5, 22.8) 0.007 1843 100 25.8 (29.4, 22.3) 0.005
Mean+ SD 50.8+20.3 44.2+15.9 50.9+20.2 45.0+17.2
Baseline BNP (pg/mL)
n 522 15 1330 (2693, 3353) 0.003 514 23 593 (2751, 1935) 0.110
Median (IQR) 1255.0 (813.0, 2204.0) 2516.2 (1120.0, 3113.0) 1270 (820, 2275) 1207 (818, 2952)
Baseline NT-proBNP (pg/mL)b
n 1460 58 1079 (21138, 3296) 0.481 1434 84 1768 (2811, 2579) 0.491
Median (IQR) 3000.0 (3000.0, 3777.6) 3000.0 (3000.0, 6471.0) 3000 (3000, 3732) 3000 (3000, 6721)
Systolic blood pressure (mmHg)
n 1959 73 23.0 (26.9, 0.8) 0.148 1926 106 26.9 (210.2, 23.5) ,0.001
Mean+ SD 124.4+17.7 121.4+16.3 125+17.6 118+17.1
Diastolic blood pressure
(mmHg)
n 1959 73 20.7 (23.6, 2.1) 0.599 1926 106 22.4 (24.7, 20.2) 0.036
Mean+ SD 73.7+11.84 73.0+12.0 74.0+11.9 71.4+11.4
Heart rate (b.p.m.)
n 1958 73 2.8 (21.1, 6.6) 0.130 1925 106 2.1 (21.2, 5.1) 0.175
Mean+ SD 80.0+15.4 82.8+16.3 80.0+15.4 82.1+16.7
Respiration rate (b.p.m.)
n 1868 70 0.3 (21.2, 1.8) 0.545 1838 100 20.1 (21.3, 1.0) 0.784
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NYHA class prior to hospitalization (%)
n 1856 69 5.0 (23.1, 13.1)
% NYHA class III or IV
0.656 1826 99 3.9 (23.2, 11.0) In %
NYHA class ¼ III or IV
0.764
Class I 0.9 1.5 1 1
Class II 17 12 17 13
Class III 51 54 51 55
Class IV 31 33 31 31
History of hypertension (%) 79 82 2.8 (26.1, 11.8) 0.553 79 79 20.2 (28.1, 7.7) 0.960
History of atrial fibrillation/
flutter (%)
55 57 2.4 (29.3, 14.1) 0.688 54 59 4.6 (25.0, 14.3) 0.350
History of congestive heart
failure (%)
95 95 20.3 (25.6, 5.0) 0.790 95 93 21.5 (26.3, 3.4) 0.509
History of diabetes mellitus
(%)
45 44 21.6 (213.2, 10.0) 0.788 45 43 22.1 (211.8, 7.6) 0.674
History of asthma, bronchitis,
or chronic obstructive
pulmonary disease (%)
20 23 3.6 (26.3, 13.5) 0.448 20 21 1.0 (26.9, 8.9) 0.803
History of ischemic heart
disease (%)
69 83 14.1 (5.2, 22.9) 0.011 69 82 12.8 (5.1, 20.4) 0.006
History of myocardial
infarction (%)
49 51 1.4 (210.4, 13.2) 0.817 49 55 5.7 (24.1, 15.6) 0.254
Previous ICD implantation (%) 16 6.9 29.5 (215.5, 23.5) 0.030 16 11 25.0 (211.2, 1.3) 0.178
History of CRT (%) 10 5.5 24.9 (210.3, 0.5) 0.172 10 7 23.8 (28.8, 1.1) 0.205
Left ventricular ejection fraction (% units)
n 939 36 1.2 (23.7, 6.1) 0.603 920 55 0.8 (23.0, 4.6) 0.666
Mean+ SD 32.3+13.1 33.5+14.3 32.3+13.1 33.1+13.9
Prior ACE-inhibitors or ARB
(%)
76 73 23.2 (213.6, 7.3) 0.538 76 72 24.2 (213.0, 4.6) 0.331
Prior b-blockers (%) 77 64 212.3 (223.4, 21.2) 0.015 77 65 211.8 (221.0, 22.5) 0.006
Prior aldosterone antagonists
(%)
44 52 8.5 (23.1, 20.2) 0.148 43 52 8.6 (21.2, 18.3) 0.085
Prior digoxin (%) 28 21 27.8 (217.3, 1.7) 0.145 29 19 28.8 (216.6, 20.9) 0.052
Prior nitrates (%) 26 32 5.7 (25.1, 16.6) 0.271 26 29 3.5 (25.4, 12.3) 0.428
ACE-inhibitors or ARB at
discharge (%)
83 50 233.0 (247.5, 218.4) ,0.001 84 51 232.8 (244.0, 221.7) ,0.001
b-Blockers at discharge (%) 85 51 234.4 (248.8, 219.4) ,0.001 86 55 230.6 (241.7, 219.4) ,0.001
Aldosterone antagonists at
discharge (%)
60 42 218.2 (232.7, 23.6) 0.014 61 46 214.4 (225.6, 23.1) 0.011
Digoxin at discharge (%) 33 22 211.3 (223.4, 0.9) 0.108 33 24 29.0 (218.7, 0.6) 0.093
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Table 3 Continued
Variable All-cause deaths at Day 14 P-value All-cause deaths at Day 30 P-value
No (n 5 1960) Yes (n5 73) Difference (95% CI)a No (n5 1927) Yes (n 5 106) Difference (95% CI)a
Days treated with study drug
(%)
n 1960 73 25.7 (234.2, 12.8) %
of days treated ¼ 3
,0.001 1927 106 216.6 (224.8, 28.3) in %
treated days ¼ 3
,0.001
0 1.5 1.4 2 1
1 2.4 19.2 2 15
2 4.1 11.0 4 9
3 92.0 68.5 92 75
Total dose of i.v. loop diuretics from Days 1 to 7 (mg)
n 1960 73 649 (346, 952) ,0.001 1927 108 614 (332, 895) ,0.001
Median (IQR) 275.6 (120.0, 531.3) 795.0 (440.0, 1140.0) 260 (120, 560) 710 (320, 1120)
Treated with i.v. inotropes/
vasopressors prior to Day
7 (%)
5.8 53 47.9 (36.2, 59.2) ,0.001 6 43 37.9 (28.4, 47.4) ,0.001
Treated with vasodilators
prior to Day 7 (%)
11 23 12.3 (2.6, 22) ,0.001 11 18 6.7 (20.5, 14) ,0.001
ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy.
aDifferences are for patients who died, compared with those who were alive, at either Day 14 or Day 30.
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placebo, at 24 and 48 h from randomization. Early relief of dys-
pnoea occurred in 301 of 663 patients (45.40%) on placebo vs.
694 of 1335 patients (51.99%) on rolofylline [OR (95% CI): 1.30
(1.08, 1.57)] with a number needed to treat with rolofylline to
achieve one early dyspnoea relief of 15 (95% CI: 9, 52; Table 7).
This difference persisted, although reduced in magnitude, to Day
14 (Figure 1). Similar results were found with respect to the assess-
ment of NYHA class with a lower proportion of patients in NYHA
class IV in the rolofylline group commencing with Day 2 up to Day
14 (Figure 2). Overall, the proportion of patients meeting criteria
for WHF was similar with rolofylline (10.5%) and placebo
[11.2%, OR (95% CI): 0.93 (0.69, 1.25)]. No differences in pre-
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Table 4 Associations between dyspnoea relief and all-cause mortality
Dyspnoea relief Hazard ratio (95% CIs)
Yes, event/total (%)a No, event/total (%)a
All patients
14 days 14/995 (1.4) 49/1003 (4.9) 0.28 (0.15, 0.50)
30 days 25/995 (2.5) 70/1003 (7.0) 0.35 (0.22, 0.55)
Age ,72 years
14 days 6/497 (1.2) 15/482 (3.1) 0.36 (0.14, 0.94)
30 days 10/497 (2.0) 24/482 (5.0) 0.38 (0.18, 0.79)
Age ≥72 years
14 days 8/498 (1.6) 34/521 (6.5) 0.24 (0.11, 0.52)
30 days 15/498 (3.0) 46/521 (8.8) 0.33 (0.18, 0.59)
NYHA class I– III
14 days 10/685 (1.5) 30/618 (4.9) 0.29 (0.14, 0.59)
30 days 19/685 (2.8) 42/618 (6.8) 0.39 (0.22, 0.67)
NYHA class IV
14 days 4/267 (1.5) 16/324 (5.0) 0.26 (0.09, 0.78)
30 days 5/267 (1.9) 23/324 (7.1) 0.24 (0.09, 0.62)
Systolic blood pressure at screening ,124 mmHg
14 days 6/458 (1.3) 28/526 (5.3) 0.24 (0.10, 0.57)
30 days 15/458 (3.3) 46/526 (8.8) 0.35 (0.20, 0.64)
Systolic blood pressure at screening ≥124 mmHg
14 days 8/536 (1.5) 21/477 (4.4) 0.34 (0.15, 0.76)
30 days 10/536 (1.9) 24/477 (5.1) 0.37 (0.18, 0.78)
BNP ≤ 750 pg/mL/NT-proBNP ≤ 3000 pg/mL
14 days 5/573 (0.9) 29/592 (4.9) 0.18 (0.07, 0.45)
30 days 11/573 (1.9) 41/592 (6.9) 0.27 (0.14, 0.53)
BNP. 750 pg/mL/NT-proBNP. 3000 pg/mL
14 days 9/421 (2.1) 19/408 (4.7) 0.41 (0.18, 0.91)
30 days 14/421 (3.3) 28/408 (6.9) 0.45 (0.24, 0.86)
Baseline creatinine ,1.5 mg/dL
14 days 6/496 (1.2) 18/430 (4.2) 0.28 (0.11, 0.72)
30 days 11/496 (2.2) 26/430 (6.1) 0.36 (0.18, 0.72)
Baseline creatinine ≥1.5 mg/dL
14 days 8/467 (1.7) 29/545 (5.3) 0.31 (0.14, 0.67)
30 days 14/467 (3.0) 41/545 (7.5) 0.38 (0.21, 0.70)
Baseline creatinine clearance ,48 mL/min
14 days 8/447 (1.8) 27/509 (5.3) 0.33 (0.15, 0.72)
30 days 14/447 (3.1) 36/509 (7.1) 0.43 (0.23, 0.80)
Baseline creatinine clearance ≥48 mL/min
14 days 6/512 (1.2) 20/457 (4.4) 0.26 (0.10, 0.65)
30 days 11/512 (2.2) 30/457 (6.6) 0.32 (0.16, 0.64)
Cut-off values for age, systolic blood pressure, serum creatinine, and creatinine clearance were the median values.
aThe Kaplan–Meier estimates.
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Table 5 Multivariable analysis of the association between dyspnoea relief and mortality at Days 14 and 30
Variable HR 95% CI P-value
14-day mortality
Dyspnoea relief at Days 2 and 3 0.34 0.18, 0.62 ,0.0001
Age, per 1 year increase 1.04 1.01, 1.07 0.021
NYHA class before admission IV vs. I/II/II 0.92 0.52, 1.63 0.780
Systolic blood pressure at screening, per 1 mmHg increase 0.99 0.98, 1.01 0.426
Screening BNP. 750 or NT-proBNP. 3000 pg/mL 1.32 0.77, 2.26 0.306
Day 1 serum sodium, per 1 mEq/L increase 0.90 0.85, 0.95 ,0.001
Baseline creatinine clearance, per 1 mL/min increase 0.99 0.97, 1.01 0.295
30-day mortality
Dyspnoea relief at Days 2 and 3 0.42 0.26, 0.67 ,0.0001
Age, per 1 year increase 1.03 1.00, 1.05 0.025
NYHA class before admission IV vs. I/II/II 0.79 0.49, 1.28 0.332
Systolic blood pressure at screening, per 1 mmHg increase 0.98 0.97, 0.99 0.004
Screening BNP. 750 or NT-proBNP. 3000 pg/mL 1.17 0.75, 1.82 0.492
Day 1 serum sodium, per 1 mEq/L increase 0.90 0.86, 0.94 ,0.001
Baseline creatinine clearance, per 1 mL/min increase 0.99 0.98, 1.01 0.252
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Table 6 Associations between worsening heart failure and all-cause mortality
WHF through Day 7 Hazard ratio (95% CI)
Yes, event/total (%)a No, event/total (%)a
All patients
14 days 25/189 (13.2) 38/1811 (2.1) 6.84 (4. 12, 11.35)
30 days 30/189 (15.9) 66/1811 (3.7) 4.78 (3.10, 7.37)
NYHA class I– III
14 days 14/128 (10.9) 26/1177 (2.2) 5.18 (2.70, 9.93)
30 days 18/128 (14.1) 44/1177 (3.8) 4.04 (2.33, 6.99)
NYHA class IV
14 days 10/48 (20.8) 10/543 (1.9) 14.40 (5.96, 34.79)
30 days 11/48 (22.9) 17/543 (3.1) 9.22 (4.28, 19.88)
Baseline creatinine ,1.5 mg/dL (median)
14 days 8/65 (12.3) 8/65 (12.3) 7.02 (2.99, 16.46)
30 days 10/65 (15.4) 27/861 (3.1) 5.42 (2.61, 11.23)
Baseline creatinine ≥1.5 mg/dL (median)
14 days 17/123 (13.8) 20/889 (2.3) 6.68 (3.49, 12.77)
30 days 20/123 (16.3) 35/889 (4.0) 4.51 (2.60, 7.83)
Baseline creatinine clearance ,48 mL/min (median)
14 days 15/109 (13.8) 20/847 (2.4) 6.17 (3.16, 12.06)
30 days 17/109 (15.6) 33/847 (3.9) 4.30 (2.39, 7.73)
Baseline creatinine clearance ≥48 mL/min (median)
14 days 10/77 (13.0) 16/892 (1.8) 8.40 (3.80, 18.58)
30 days 13/77 (16.9) 28/892 (3.1) 6.32 (3.26, 12.24)
aThe Kaplan–Meier estimates.
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defined subgroups based on NYHA class before hospitalization,
serum creatinine, or creatinine clearance at baseline were found
(Table 7).
The duration of hospital stay was numerically shorter with rolo-
fylline, compared with placebo [mean+ SD, 14.5+ 20.8 vs.
16.0+23.8 days; treatment difference (95% CI) 21.54 (23.56,
0.48) days] (Table 7). Days 14 and 30 and in-hospital mortality
are presented in Figure 3. Hazard ratios (95% CI) for all-cause mor-
tality for rolofylline vs. placebo at Days 14 and 30 were 0.80 (0.50,
1.29) and 0.86 (0.56, 1.27), respectively. These results were largely
driven by mortality due to HF [30-day HF mortality, HR (95% CI):
0.65 (0.38, 1.1); Figure 3]. Overall mortality to Day 180 was not
different between placebo and rolofylline (17.6 vs. 18%, respect-
ively), but HF mortality was numerically lower also at Day 180
(8.3 vs. 10.8%).
Discussion
In the PROTECT study, about half of the patients did not achieve
marked or moderate relief of dyspnoea within 24 h, and 10.7%
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 7 Effects of rolofylline on dyspnoea relief and worsening heart failure: subgroup analysis





Dyspnoea relief, no. of patients/total (%)
NYHA class I– III 211/441 (47.9) 474/862 (55.0) 1.34 (1.06, 1.68)
NYHA class IV 77/190 (40.5) 190/401 (47.4) 1.33 (0.94, 1.90) 0.971
Baseline creatinine ,1.5 mg/dL (132.6 mmol/L) (median) 158/326 (48.5) 338/600 (56.3) 1.37 (1.04, 1.80)
Baseline creatinine ≥1.5 mg/dL (132.6 mmol/L) (median) 132/317 (41.6) 335/695 (48.2) 1.30 (1.00, 1.71) 0.795
Baseline creatinine clearance ,48 mL/min (median) 127/301 (42.2) 320/655 (48.9) 1.31 (1.00, 1.73)
Baseline creatinine clearance .48 mL/min (median) 162/340 (47.7) 350/629 (55.6) 1.38 (1.06, 1.80) 0.790
Worsening heart failure, no. of patients/total (%)
NYHA class I– III 50/444 (11.3) 93/867 (10.7) 0.95 (0.66, 1.36)
NYHA class IV 21/192 (10.9) 37/402 (9.2) 0.83 (0.47, 1.45) 0.689
Baseline creatinine ,1.5 mg/dL(132.6 mmol/L) (median) 28/327 (8.6) 51/602 (8.5) 0.98 (0.61, 1.59)
Baseline creatinine ≥1.5 mg/dL (132.6 mmol/L) (median) 46/319 (14.4) 88/699 (12.6) 0.85 (0.58, 1.25) 0.644
Baseline creatinine clearance ,48 mL/min (median) 40/304 (13.2) 82/658 (12.5) 0.95 (0.63, 1.42)
Baseline creatinine clearance ≥48 mL/min (median) 33/340 (9.7) 56/632 (8.9) 0.91 (0.58, 1.44) 0.903
Length of hospitalization (days)
NYHA class I– III
Mean+ SD 14.3+23.4 13.0+19.8 21.33 (23.74, 1.08)
Median (IQR) 7.0 (5.0, 12.0) 7 (5.0, 12.0)
NYHA class IV
Mean+ SD 19.3+24.9 16.8+20.7 22.40 (26.17, 1.36) 0.622
Median (IQR) 13 (7.0, 17.5) 12.0 (7.0, 18.0)
Baseline creatinine ,1.5 mg/dL (132.6 mmol/L) (median)
Mean+ SD 13.9+19.7 14.3+20.2 0.23 (22.45, 2.91)
Median (IQR) 8.0 (6.0, 14.0) 8.0 (6.0, 15.0)
Baseline creatinine ≥1.5 mg/dL (132.6 mmol/L) (median)
Mean+ SD 17.9+26.9 14.9+21.4 23.06 (26.14, 0.01) 0.103
Median (IQR) 8.0 (6.0, 15.0) 8.0 (6.0, 14.0)
Baseline creatinine clearance ,48 mL/min (median)
Mean+ SD 17.0+25.4 15.4+22.9 21.38 (24.6, 1.85)
Median 8.0 (6.0, 15.0) 8.0 (6.0, 14.0)
Baseline creatinine clearance ≥48 mL/min (median)
Mean+ SD 14.8+21.6 13.8+18.5 21.14 (23.72, 1.44) 0.815
Median (IQR) 8.0 (6.0, 15.0) 8.0 (6.0, 15.0)
aTreatment difference was measured as OR (rolofylline/placebo) for dyspnoea relief and worsening heart failure, and difference in means (rolofylline–placebo) for length of
hospital stay.
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developed WHF during the first week of hospitalization. Lack of dys-
pnoea relief and WHF were each associated with increased mortality
at 14 and 30 days and this relation persisted after adjustment for
other variables known to affect outcomes in patients with AHF.
Rolofylline administration was associated with a greater decline in
body weight, more patients obtaining early dyspnoea relief and a
non-significant, although numerically lower, mortality in the first
month, which was mostly due to fewer deaths caused by HF.
The results of the present study are consistent with those of the
previously published PROTECT Pilot trial. Favourable effects of
rolofylline on dyspnoea and a relation between dyspnoea relief
and short-term outcomes were shown also in that study.25,28
However, the lack of effects of rolofylline on serum creatinine
levels and its untoward central nervous system effects became
evident only in the much larger main PROTECT trial.26 These dis-
crepancies emphasize the need to perform large multicentre trials
in order to confirm favourable findings from smaller pilot studies
and evaluate drug safety.11
Clinical significance of dyspnoea relief
Dyspnoea relief was a main component of the primary endpoint in
PROTECT. This variable has been criticized as an endpoint
because it is subjective, difficult to measure, and can be expected
to improve in the control group because of concomitant treat-
ments.2,11,29 However, it is the main cause of hospitalization for
the patients with AHF, has been used as primary endpoint in vir-
tually all AHF trials,6– 9,25,29 and has shown differences between
active treatment and placebo in most of them.6 –8
In the PROTECT study, the proportion of patients who achieved
moderate or marked dyspnoea relief at 24 and 48 h was low
(49.8%). This value was, however, similar to that found in the
pilot study of PROTECT (54%)25 and to that shown by an obser-
vational study regarding early changes in dyspnoea after an admis-
sion for AHF.30,31 Our proportion of patients improving was,
however, lower compared with previous studies where 65% of
the patients assigned to placebo showed an early improvement
of dyspnoea.6,7 This may relate to the definition of dyspnoea
relief (i.e. a moderate to marked better dyspnoea at both Days 2
and 3) as well as the inclusion criteria of the study, including
signs of fluid overload, need of i.v. diuretic therapy, underlying
renal dysfunction, and, most importantly, elevated natriuretic pep-
tides plasma levels, probably excluding patients with non-cardiac
causes of dyspnoea and with mild HF.32 Our results suggest that
current AHF therapy is suboptimal not only with respect to out-
comes but also with respect to symptom relief.30,31
In the present study, dyspnoea relief was associated with lower
all-cause mortality at both 14 and 30 days. However, only a few
baseline variables (NYHA class before admission, renal impair-
ment) were different between patients with and without dyspnoea
relief, underlining our limited understanding of the pathophysiology
of AHF and of, specifically, pulmonary congestion.12,33 Measure-
ment of left ventricular ejection fraction could have increased
the predictive value of the model. This variable was not assessed
and reported systematically in PROTECT as the drug was per-
ceived to act trough effects on fluid retention and renal protection.
Effects of rolofylline
In the PROTECT study, early dyspnoea relief was associated
with a greater decline in body weight and rolofylline induced
more weight loss and dyspnoea relief, compared with placebo.
These effects are consistent with rolofylline’s mild diuretic
action and confirm data from previous studies with adenosine
A1 receptor antagonists.23,24 These agents inhibit sodium
reuptake in the proximal tubule and may therefore enhance
the effects of loop diuretics.
Although the effects of rolofylline on dyspnoea may be
deemed as small [OR (95% CI): 1.30 (1.08, 1.57) for achieve-
ment of dyspnoea relief with rolofylline vs. placebo], they are
of larger magnitude than those reported with other drugs cur-
rently approved for the treatment of AHF in many
countries6– 8 as well as with those achieved by a 2.5-fold
increase in furosemide dose in the Diuretic Optimization Strat-
egies Evaluation (DOSE) Study.34 In that trial, the administration
of higher doses of furosemide was associated with a slight
improvement in dyspnoea relief and weight loss and with a
Figure 1 Change in dyspnoea by day and treatment group
(solid bars, placebo; hatched bars, rolofylline). Changes in dys-
pnoea were ranked based on the Likert scale: 23, markedly
worse; 22, moderately worse; 21, minimally worse; 0, no
change; 1, minimally better; 2, moderately better; 3, markedly
better.
Figure 2 New York Heart Association class by day and treat-
ment group (solid bars: placebo; hatched bars, rolofylline).
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Figure 3 All-cause mortality, heart failure (HF) mortality, and cardiovascular (CV) mortality to Days 14 and 30 by treatment for all subjects (A) and subjects subdivided by baseline serum
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transient increase in creatinine (seemingly larger than that
reported in PROTECT). Although a head-to-head comparison
of rolofylline and high-dose furosemide was not performed,
these data show that enhanced diuresis (either by more i.v. fur-
osemide or rolofylline), in patients with fluid overload and high
natriuretic peptide levels, can have some beneficial effects on
symptoms, even in the absence of any favourable effect on
kidney function or while leading to some mostly transient crea-
tinine increases.
In contrast to the results from studies with the treatment of
chronic HF1,3 as well as with coronary revascularization in patients
with acute myocardial infarction, the non-significant numerically
smaller number of early deaths in the rolofylline- vs. placebo-
treated patients did not persist after 30 days, suggesting that
there it may be a chance finding. However, the fact that these
effects were mostly driven by disease-specific (i.e. HF) mortality,
while non-disease-specific mortality was not affected, increases
the likelihood that they represent a real effect. Secondly, patients
admitted for AHF are older and have substantial background mor-
bidity. Such non-cardiovascular or non-HF co-morbidities have a
strong impact on prognosis,1,16,35 but HF-specific therapies may
have limited effectiveness on them. Indeed, numerically lower HF
mortality was observed at 180 days from enrolment, but the
effect on all-cause mortality was diluted by death from other
causes. Thirdly, episodes of AHF may represent the manifestation
of advanced to end-stage HF, a condition in which medical treat-
ment is less likely to improve effectively long-term prognosis.36
Finally, it is likely that an intervention with favourable effects
needs to be repeated rather than administered only once in the
context of a randomized trial, to be effective. These observations
suggest that a short-term treatment associated with early symp-
toms improvement is more likely to have an impact on short-term
outcomes, whereas long-term outcomes are more dependent on
co-morbidities and mechanisms causing disease progression.
Most importantly, the present analyses suggest that short-term
outcomes may be strongly related with early dyspnoea relief and
that different from previous trials,5,7 symptoms’ improvement
may be associated with a neutral, if not better, short-term
outcome.
Limitations
Although the dyspnoea relief endpoints examined in the present
manuscript were pre-defined as components of the primary end-
point, their separate analysis was not pre-defined in the
PROTECT programme. PROTECT was not powered to detect a
modest effect of rolofylline on mortality and its effects on short-
term mortality constituted a post hoc analysis. Hence, these
results cannot be regarded as definitive. With respect of subgroup
analysis, baseline serum creatinine, estimated creatinine clearance,
and NYHA class were identified as of interest a priori and included
in the subgroup analysis for the primary and secondary endpoints
of PROTECT.26 They were included also in the present study,
although their relation with short-term outcomes is a post hoc
analysis. As no differences between rolofylline and placebo were
present with respect to baseline characteristics, no adjustment
for baseline characteristics by multivariable analysis was performed
in the present analysis. An assessment of the clinical significance of
symptoms relief and short-term outcomes would need adjustment
for baseline data.
Severity of symptoms at baseline may influence their changes
after treatment.30,31 Although it is possible that some patients
did not report improvement because their symptoms were not
particularly severe at baseline, the selection criteria for the study
favoured inclusion of more severe patients. Patients who did not
have dyspnoea relief had more high-risk features and had three
to four times higher mortality, suggesting that the lack of dyspnoea
relief occurred for the most part in sicker patients who did not
improve with current available therapies. Unfortunately, no data
regarding the severity of symptoms at baseline were collected in
PROTECT except for NYHA class as dyspnoea was measured
using the Likert scale to compare the severity of breathlessness
with baseline values.
Conclusions
Using objective inclusion criteria based on plasma natriuretic pep-
tides, marked or moderate dyspnoea relief at 24 and 48 h occurred
in slightly ,50% of patients in the PROTECT study. Early dyspnoea
relief was associated with lower short-term (30 days) mortality.
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Percutaneous implantation of an Edwards SAPIEN valve in a failing
pulmonary bioprosthesis in palliated Tetralogy of Fallot
Simon T. MacDonald, Mario Carminati , and Gianfranco Butera*
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A 15-year-old boy with Tetralogy of Fallot, palliated neonatally by
transannular patch repair, had a surgical 25 mm Perimount pericardial
pulmonary bioprosthesis following the development of severe pul-
monary regurgitation (PR) with severe right ventricular (RV) dilatation
aged 10. Now with moderate exercise capacity reduction and further
RV dilation and PR following bioprosthesis degeneration, it was elected
to implant another pulmonary valve percutaneously.
Angiography showed severe PR with a dilated pulmonary root and
outflow tract (Panel A, bioprosthesis inset). The bioprosthetic valve
annulus provided support in the outflow tract. After initial positioning
(Panel B), a balloon expandable Edwards SAPIEN 26 mm valve was
deployed via the right femoral vein using the Edwards Retroflex 2
Transfemoral Delivery System (Panel C). Angiography confirmed
good valve position and PR resolution (Panel D, valve-in-valve inset).
This is the first percutaneous ‘valve in valve’ Edwards SAPIEN valve
implanted in a patient with a bioprosthetic pulmonary valve without a
conduit/prestenting. This is an ‘off-label’ use of the device but percuta-
neous pulmonary valve implantation is accepted as a less invasive and
safe way to improve haemodynamics following RV outflow tract repair
and re-emergence of outflow-tract stenosis and/or PR with RV dysfunction. Outflow tract size is critical in considering whether a con-
ventional Melody valve (used in RV–PA conduits measuring less than 22 mm) or Edwards SAPIEN valve (available in 23 or 26 mm
sizes) can be used. A valve in valve approach here allowed treatment of the RV outflow tract without the risk associated with
further sternotomy, a reduced hospital stay, and may be an option in those with previous bioprosthetic valves.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2011. For permissions please email: journals.permissions@oup.com
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